Jianli Wang

Title: Innovations in Sepsis Treatment by Jianli Wang

Introduction

Jianli Wang is a notable inventor based in Tianjin, China. He has made significant contributions to the field of pharmaceutical compositions, particularly in the treatment of sepsis. His innovative work has led to the development of effective treatments that are both safe and efficacious.

Latest Patents

Jianli Wang holds a patent for a pharmaceutical composition aimed at treating sepsis. This composition includes a three-component formulation consisting of hydroxysafflower yellow A (HSYA), paeoniflorin, and albiflorin. Additionally, he has developed a more complex seven-component formulation that incorporates HSYA, paeoniflorin, albiflorin, oxypaeoniflorin, senkyunolide I, salvianic acid A sodium (SAAS), and ferulic acid. Both formulations have been verified at the cellular and animal levels for their efficacy in treating sepsis, while also demonstrating safety in drug toxicity experiments. This pharmaceutical composition serves as an active ingredient in the Xuebijing Injection, which is utilized for clinical treatment of sepsis.

Career Highlights

Jianli Wang is associated with Tianjin Chase Sun Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on clinical practices in treating sepsis.

Collaborations

Jianli Wang collaborates with notable colleagues such as Yang Yu and Chunliang Jiang, contributing to a dynamic research environment focused on innovative pharmaceutical solutions.

Conclusion

Jianli Wang's contributions to the field of pharmaceutical compositions for treating sepsis highlight his role as an influential inventor. His innovative formulations not only demonstrate efficacy but also prioritize patient safety, marking a significant advancement in medical treatments.